Transcenta Holding Future Growth

Future criteria checks 1/6

Transcenta Holding's earnings are forecast to decline at 2.4% per annum while its annual revenue is expected to grow at 19.2% per year. EPS is expected to decline by 1.9% per annum.

Key information

-2.4%

Earnings growth rate

-1.9%

EPS growth rate

Biotechs earnings growth	36.2%
Revenue growth rate	19.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	28 Mar 2024

Recent future growth updates

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15

Earnings and Revenue Growth Forecasts

SEHK:6628 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	76	-481	-396	N/A	1
12/31/2025	176	-457	-547	-2,643	2
12/31/2024	161	-309	-964	-545	1
12/31/2023	54	-463	-374	-358	N/A
9/30/2023	85	-451	-364	-343	N/A
6/30/2023	116	-440	-355	-329	N/A
3/31/2023	109	-424	-336	-312	N/A
12/31/2022	102	-407	-318	-296	N/A
9/30/2022	74	-666	-371	-337	N/A
6/30/2022	45	-925	-424	-377	N/A
3/31/2022	53	-1,748	-467	-419	N/A
12/31/2021	50	-1,716	-440	-384	N/A
9/30/2021	65	-1,457	-377	-321	N/A
6/30/2021	79	-1,199	-314	-258	N/A
3/31/2021	82	-364	-256	-180	N/A
12/31/2020	81	-317	-238	-174	N/A
12/31/2019	44	-395	-457	-235	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6628 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6628 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6628 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6628's revenue (19.2% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).

High Growth Revenue: 6628's revenue (19.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 6628's Return on Equity is forecast to be high in 3 years time

Transcenta Holding Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus revenue estimates decrease by 17%, EPS upgraded

Recent updates

Transcenta Holding Limited Announces Board and Nomination Changes

New minor risk - Market cap size

Consensus revenue estimates decrease by 17%, EPS upgraded

Transcenta Holding Limited, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥1.14 loss per share (vs CN¥0.94 loss in FY 2022)

Transcenta Holding Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO & Executive Director recently bought HK$74k worth of stock

Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.47 loss in 1H 2022)

Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023

Transcenta Holding Limited to Report First Half, 2023 Results on Aug 22, 2023

Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)

CEO & Executive Director recently bought HK$50k worth of stock

Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab (TST001)

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$54k worth of stock

Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023

Transcenta Holding Limited Announces Completion of Enrollment in COHorts C and G of China Phase II Study of Osemitamab (TST001) in Combination with Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$72k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Transcenta Holding Limited to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Transcenta Receives IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces Appointment of Independent Non-Executive Director and Change in the Composition of Board Committees

High number of new and inexperienced directors

CEO & Executive Director recently bought HK$78k worth of stock

Transcenta Holding Limited Provides Update on Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma

Transcenta Holding Limited Receives IND Clearance from FDA for its MASP2 Targeting Antibody TST004 for Treatment of IgA Nephropathy

CEO & Executive Director recently bought HK$72k worth of stock

Transcenta Holding Limited Receives IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces that Interim Safety and Efficacy Data of Dose Expansion Cohort from the Phase I/II Study of TST001 (Osemitamab)

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

First half 2022 earnings released: CN¥0.47 loss per share (vs CN¥10.19 loss in 1H 2021)

Transcenta Holding Limited to Report First Half, 2022 Results on Aug 29, 2022

Transcenta Holding Limited Announces the Appointment of Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Transcenta Holding Limited Announces Change of the Chief Medical Officer

Transcenta Holding Limited Announces Resignation of Michael Ming Shi as Executive Director

Transcenta Holding Limited Announces That It Was Selected to Present the Preclinical Data of Tst004 At the 2022 Isn Frontiers Meetings of Complement-Related Kidney Diseases

Transcenta Holding Limited Announces Demise of Albert Da Zhu, an Executive Director and a Joint Company Secretary

Transcenta Holding Limited Publishes the Results of Preclinical Studies of the Company's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Castration Resistant Prostate Cancer

Less than half of directors are independent

Transcenta Holding Limited Successfully Passes the Audit of EU Qualified Person for the Manufacturing of TST001

CEO & Executive Director recently bought HK$59k worth of stock

Transcenta Holding Limited, Annual General Meeting, Jun 10, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Transcenta Holding Limited to Present Two Phase I Clinical Trials of Tst001 at Upcoming ASCO GI and IGCC

CEO & Executive Director recently bought HK$864k worth of stock

Transcenta Holding Limited Announces Business Update on the First Patient Dosed in Thephase Ib Clinical Trial of Humanized Anti-Vegfr-2Monoclonal Antibody Msb0254

Transcenta Holding Limited has completed an IPO in the amount of HKD 645.28 million.

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies